
The UK Financial Conduct Authority has put Credit Suisse on a watchlist of companies needing tougher supervisions, a Financial Times (FT) report says.
According to the FCA, Credit Suisse may not have done enough to “improve its culture, governance and risk controls.” Regulators reportedly thought the bank needed to provide evidence of what it would do to prevent misconduct and improve accountability, along with addressing what it said were “persistent” cultural issues like a lack of internal challenges for risky transactions.
Credit Suisse has reportedly had numerous scandals in the last two years, which the report says have exposed weak risk controls and forced the bank to issue several profit warnings, damaging its share price.
Among the scandals was the way Greensill Capital imploded in March of 2021. That incident caused Credit Suisse to shut down $10 billion in funds related to the supply chain group. And only weeks after, the company lost $5.5 billion in the biggest trading loss in its history.
The FCA signals the seriousness of the situation with this designation, as the watchlist only scrutinizes around 20 or so institutions.
Groups on the list are closely watched by high officials with the FCA, and have to show progress by addressing the root causes of concern.
PYMNTS wrote that Credit Suisse in February was trying to curb the fallout in the wake of revelations that there had been 18,000 leaked accounts connected to criminals, alleged human rights abusers and sanctioned people including dictators.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas